Q-omics provides the consensus-scored DUXAP5 profile across patient tissues and cancer cell-line models. DUXAP5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DUXAP5 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, DUXAP5 RNA expression shows 6,025 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where DUXAP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUXAP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUXAP5 survival associations across molecular data types. DUXAP5 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUXAP5 RNA expression–survival associations across cancer types. High DUXAP5 expression shows unfavorable associations in LUAD, THYM, SKCM, KICH and LGG, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .013). Together, the overview and detailed table identify KIRC as the clearest survival context for DUXAP5 RNA expression.
This table summarizes DUXAP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DUXAP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUXAP5 shows lower tumor expression in KIRP and KIRC and higher tumor expression in HNSC and KIRP. The HNSC box plot shows higher DUXAP5 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p = .040).
This table shows molecular features associated with DUXAP5 in patient tissues and cancer cell lines. In patient samples, DUXAP5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
